ELOCTATE 250

Country: Իսրայել

language: անգլերեն

source: Ministry of Health

active_ingredient:

COAGULATION FACTOR VIII

MAH:

SANOFI - AVENTIS ISRAEL LTD

ATC_code:

B02BD05

pharmaceutical_form:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

composition:

COAGULATION FACTOR VIII 250 IU

administration_route:

I.V

prescription_type:

Required

manufactured_by:

BIOGEN IDEC LIMITED , UK

therapeutic_area:

COAGULATION FACTOR VII

therapeutic_indication:

ELOCTATE [Antihemophilic Factor (Recombinant Fc Fusion Protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with Hemophilia A (congenital factor VIII deficiency) for:• Control and prevention of bleeding episodes.• Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• Perioperative management (surgical prophylaxis).ELOCTATE is not indicated for the treatment of von Willebrand disease.

authorization_date:

2017-01-09